HPV prevalence around the time of sexual debut in adolescent girls in Tanzania.
Africa
HPV
adolescent
vaccination
Journal
Sexually transmitted infections
ISSN: 1472-3263
Titre abrégé: Sex Transm Infect
Pays: England
ID NLM: 9805554
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
18
02
2019
revised:
07
05
2019
accepted:
13
05
2019
pubmed:
22
6
2019
medline:
24
6
2020
entrez:
22
6
2019
Statut:
ppublish
Résumé
Cervical cancer is the leading cause of cancer-related mortality among women in sub-Saharan Africa (SSA). Data on human papillomavirus (HPV) epidemiology in adolescent girls in SSA are essential to inform HPV vaccine policy recommendations for cervical cancer prevention. We assessed the burden of HPV infection, and risk factors for infection, among adolescent girls around the time of sexual debut. Cross-sectional study of secondary school girls aged 17-18 years in Tanzania. Consenting participants provided samples for HPV and STI testing. Vaginal swabs were tested for 37 HPV genotypes by Roche Linear Array. Logistic regression was used to identify factors associated with HPV infection. Y chromosome was tested as a marker of recent condomless sex. 163/385 girls (42.3%) reported previous penetrative sex. HPV was detected in 125/385 (32.5%) girls, including 84/163 (51.5%) girls reporting previous sex and 41/222 (18.5%) reporting no previous sex. High-risk (HR) genotypes were detected in 70/125 (56.0%) girls with HPV infection. The most common HR genotype was HPV-16 (15/385; 3.9%). The prevalence of other HR HPV vaccine genotypes was between 0.8% and 3.1%. Among 186 girls who reported no previous sex, were negative for Y chromosome, and had no STI, 32 (17%) had detectable HPV. HPV prevalence among adolescent girls around the time of sexual debut was high. However, prevalence of most vaccine genotypes was low, indicating that extending the age range of HPV vaccination in this region may be cost-effective.
Identifiants
pubmed: 31221744
pii: sextrans-2019-054012
doi: 10.1136/sextrans-2019-054012
pmc: PMC7167299
mid: EMS83444
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
211-219Subventions
Organisme : Medical Research Council
ID : MR/R010161/1
Pays : United Kingdom
Informations de copyright
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: DWJ has received research grants from GSK Biologicals for HPV vaccine-related research.
Références
Am J Obstet Gynecol. 2019 Jul;221(1):9-18.e8
pubmed: 30550767
Vaccine. 2006 Aug 31;24 Suppl 3:S3/52-61
pubmed: 16950018
BMC Microbiol. 2012 May 30;12:83
pubmed: 22647069
Sex Transm Infect. 2019 Aug;95(5):374-379
pubmed: 30636707
Lancet Oncol. 2009 Apr;10(4):321-2
pubmed: 19350698
Int J Cancer. 2012 Jul 1;131(1):106-16
pubmed: 21858807
AIDS. 2012 Nov 13;26(17):2211-22
pubmed: 22874522
J Adolesc Health. 2016 Mar;58(3):295-301
pubmed: 26725717
BMJ Open. 2017 Jul 17;7(7):e015653
pubmed: 28716790
Sex Transm Infect. 2013 Aug;89(5):358-65
pubmed: 23486859
PLoS One. 2014 Aug 22;9(8):e105998
pubmed: 25148517
Obstet Gynecol. 1994 May;83(5 Pt 1):735-7
pubmed: 8164934
Sex Transm Infect. 2019 May;95(3):219-227
pubmed: 30518620
Gynecol Oncol. 2017 Jul;146(1):196-204
pubmed: 28442134
J Infect Dis. 2014 Sep 15;210(6):837-45
pubmed: 24740630
J Infect Dis. 2002 Aug 15;186(4):462-9
pubmed: 12195372
Am J Obstet Gynecol. 2013 Dec;209(6):505-23
pubmed: 23659989
Clin Microbiol Infect. 2019 Jan;25(1):35-47
pubmed: 29729331
J Infect Dis. 2010 Dec 15;202(12):1789-99
pubmed: 21067372
Am J Epidemiol. 2003 Feb 1;157(3):218-26
pubmed: 12543621
Dis Markers. 2007;23(4):213-27
pubmed: 17627057
Contraception. 2013 Sep;88(3):387-95
pubmed: 23312930
Vaccine. 2012 Nov 20;30 Suppl 5:F24-33
pubmed: 23199964
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Infect Dis. 2005 Jan 15;191(2):182-92
pubmed: 15609227
Infect Agent Cancer. 2010 Apr 09;5:7
pubmed: 20380709